Biological Age Estimation Tools Show Promise for Early Risk Detection, but Clinical Translation Requires Further Validation

A comprehensive review published in The Journal of Clinical Investigation maps the rapidly evolving landscape of biological age (BA) estimation, detailing how scientists are moving beyond simple calendar years to capture individual-level variability in aging through molecular profiling, artificial intelligence, and digital biomarkers. The review, authored by Cheema and colleagues, underscores both the transformative potential of these tools and the substantial gaps that remain before they can be integrated into routine patient care.

People of the same sex, born in the same year, with similar clinical profiles can differ markedly in their physical abilities, immune resilience, disease susceptibility, and overall survival. This variability reflects the cumulative effects of aging shaped by environmental exposures, health behaviors, genetic predisposition, molecular changes, and chance events. Biological age aims to capture these individual-level differences that chronological age alone cannot explain.

The Three Generations of Epigenetic Clocks

The evolution of biological age estimation can be understood through successive generations of epigenetic clocks, each designed to answer a different question about human aging. First-generation clocks, including the 2013 Horvath multi-tissue clock (which uses 353 distinct CpG sites) and the 2013 Hannum clock (which evaluates 71 CpG sites optimized for whole blood), were trained using supervised machine learning to predict chronological age. These models minimize the statistical gap between predicted age and calendar age.

Second-generation clocks shifted focus toward phenotypic health and mortality risk. The PhenoAge model incorporates nine distinct clinical laboratory measurements alongside 513 CpG sites to predict overall health risks, while the GrimAge model tracks 1,030 CpG sites correlated with plasma proteins to estimate total mortality risks. These models show strong predictive capabilities for chronic disease onset and are preferred when calculating prospective patient health spans.

Third-generation clocks, exemplified by DunedinPACE, measure the current rate of biological aging rather than a static age estimate. The next generation of clocks under development aims to measure organ-specific biological age, with newer tools such as Systems Age, OMICmAge, GlycanAge, and MileAge quantifying changes across multiple organ systems, immune cell populations, and metabolic pathways.

Beyond DNA Methylation: Digital and Functional Approaches

The review highlights that BA estimation now extends well beyond methylation-based clocks. Proteomic aging clocks can analyze thousands of proteins using regression models to estimate biological age, health span, disease susceptibility, and mortality risk. Digital AI models analyze imaging, electrophysiology, wearable signals, and clinical text, while large language model-based approaches have shown promise for estimating phenotypic aging from routinely collected health examination reports and electronic health records.

Functional markers continue to play a role. Decreases in gait speed and grip strength are associated with poorer physical function and higher mortality risks, and new models are using video-derived and computer-based analyses to make these assessments more scalable. Deep learning models can estimate brain age from MRI scans and high-resolution retinal blood vessel images, while advanced machine learning models can predict survival outcomes in cancer patients using facial imaging.

Cardiovascular and renal biomarkers also contribute to BA estimation. Elevated levels of natriuretic peptides such as NT-proBNP (search)Search target can help estimate long-term cardiovascular disease risk at levels far below standard measures, and cystatin C (search)Search target, a renal marker, has outperformed traditional creatinine-based indices in predicting mortality risks.

Tissue-Specific Aging and Disease Associations

Epigenetic aging is not uniform across the body. The cerebellum, a brain structure at the base of the skull that controls motor movement, exhibits uniquely slow biological aging compared to other brain structures. Research has confirmed that the cerebellum remains biologically younger than the cerebral cortex within the same individual, and this internal age gap widens as an individual reaches advanced old age. This resistance to aging offers clues for researchers studying progressive neurodegenerative conditions.

Age acceleration—the numerical difference between calculated biological age and actual chronological age—has been linked to multiple chronic conditions. Elevated epigenetic age acceleration in post-mortem brain tissue correlates directly with rapid pre-death cognitive decline in Alzheimer's disease (search)Search disease, a relationship that persists even after controlling for physical amyloid plaque buildup. In breast cancer (search)Search disease, elevated acceleration signs in tumor-adjacent breast tissue serve as early risk markers for future oncological growth.

Twin studies indicate that epigenetic age acceleration has a heritability rate of approximately 40%, with the remaining variance stemming from non-genetic environmental factors and cumulative lifestyle habits.

Clinical Applications and Ongoing Challenges

Clinical trials are already using epigenetic measurements as endpoints to determine whether candidate compounds slow human aging. The longitudinal monitoring protocol follows a sequential pipeline: a baseline clock check, a 6-month intervention period, and a molecular re-test. Declining age acceleration scores suggest that an intervention is successfully altering cellular metabolism.

However, the review identifies several critical challenges that must be addressed before clinical translation can occur. There is no standardized, unified framework for determining an adequate biological age measure. Most BA models rely on cross-sectional analyses and prognostic information rather than prospective longitudinal data. Head-to-head comparisons of methodological reliability, response to treatments, feasibility, and long-term stability are needed to understand whether changes in BA measurements reflect real improvements or declines in health.

Technical measurement biases also pose problems. Different laboratories using conflicting array platforms can produce batch effects that create false variations in age scores. Environmental factors such as current tobacco use, acute psychological stress, and changing sleep patterns act as major confounders that analysts must statistically adjust for to isolate true underlying aging signals.

Perhaps most fundamentally, the exact causal links between DNA methylation shifts and cellular death remain unknown. Scientists have not yet determined whether methylation changes actively drive the aging process or merely record passing cellular damage. As the review notes, predictive association does not prove causal modifiability, and researchers must determine whether lowering a BA estimate corresponds to meaningful improvements in health span, function, or survival.

The Path Forward

The review concludes that coordinated interdisciplinary efforts and increased investment in healthcare services to link BA measures with clinical outcomes will be essential to close existing gaps. Prospective studies including human participants and unified testing measures are required to accelerate clinical translation. Principal investigators are encouraged to preregister complete analytic pipelines in public registries before beginning data analysis to prevent teams from testing multiple clocks until finding a desirable statistical result.

Pending prospective validation, clinicians may eventually use these approaches to identify high-risk individuals and support more personalized prevention or treatment strategies. For now, their role in routine care remains unresolved, and bioethicists recommend careful deployment to avoid insurance discrimination based on biological age scores. Patients must receive clear counseling that biological age scores represent malleable risks rather than fixed outcomes.